ALS drug safety check: oral edaravone passes extended trial

NCT ID NCT05568615

Completed Disease control Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the medicine was safe to use over a longer period.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS

Contacts and locations

Locations

Fukushima Medical University Hospital

Fukushima, Fukushima, 960-1295, Japan
Kagawa University Hospital

Kita-gun, Kagawa-ken, 761-0793, Japan
Kitasato University Hospital

Sagamihara-shi, Kanagawa, 252-0375, Japan
National Epilepsy Center NHO Shizuoka Institute of Epilepsy and Neurological Disorders

Shizuoka, 420-8688, Japan
National Hospital Organization Chibahigashi National Hospital

Chiba, Chiba, 260-8712, Japan
National Hospital Organization Higashinagoya National Hospital

Nagoya, Aichi-ken, 465-8620, Japan
National Hospital Organization Kumamoto Saishun Medical Center

Kōshi, Kumamoto, 861-1196, Japan
National Hospital Organization Osaka Toneyama Medical Center

Toyonaka-shi, Osaka, 560-8552, Japan
Shiga University of Medical Science Hospital

Ōtsu, Shiga, 520-2192, Japan
Tokyo Metropolitan Neurological Hospital

Fuchu-shi, Tokyo, 183-0042, Japan
Yokohama City University Hospital

Yokohama, Kanagawa, 236-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.